

## News Releases

All Years

Search

Go

[Advanced Search](#)

**JUN 15, 2026**

**Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma**

**MAY 14, 2026**

**Inhibrx Reports First Quarter 2026 Financial Results**

**MAY 11, 2026**

**Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy**

**MAY 8, 2026**

**Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC**

**APR 21, 2026**

**Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer**

**APR 20, 2026**

**Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer**

**MAR 19, 2026**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial**

## Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

MAR 2, 2026

## Inhibrx Announces Participation in Upcoming Scientific Conference

DEC 16, 2025

## Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

NOV 14, 2025

## Inhibrx Reports Third Quarter 2025 Financial Results

Show  per page

« 1 2 3 4 5 6 7 8 »



<https://inhibrx.investorroom.com/news-releases?l=10>